RIGL vs. CLDX, NVAX, OPK, INVA, GERN, MYGN, VSTM, EBS, VNDA, and XOMA
Should you be buying Rigel Pharmaceuticals stock or one of its competitors? The main competitors of Rigel Pharmaceuticals include Celldex Therapeutics (CLDX), Novavax (NVAX), OPKO Health (OPK), Innoviva (INVA), Geron (GERN), Myriad Genetics (MYGN), Verastem (VSTM), Emergent BioSolutions (EBS), Vanda Pharmaceuticals (VNDA), and XOMA (XOMA). These companies are all part of the "biotechnology" industry.
Rigel Pharmaceuticals vs.
Rigel Pharmaceuticals (NASDAQ:RIGL) and Celldex Therapeutics (NASDAQ:CLDX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, community ranking, analyst recommendations, valuation and media sentiment.
In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 5 mentions for Rigel Pharmaceuticals and 3 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.07 beat Rigel Pharmaceuticals' score of 0.56 indicating that Celldex Therapeutics is being referred to more favorably in the news media.
Rigel Pharmaceuticals has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500.
66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 9.0% of Rigel Pharmaceuticals shares are owned by insiders. Comparatively, 3.8% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Celldex Therapeutics received 155 more outperform votes than Rigel Pharmaceuticals when rated by MarketBeat users. Likewise, 75.21% of users gave Celldex Therapeutics an outperform vote while only 68.98% of users gave Rigel Pharmaceuticals an outperform vote.
Rigel Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Rigel Pharmaceuticals has a net margin of 2.46% compared to Celldex Therapeutics' net margin of -1,544.32%. Rigel Pharmaceuticals' return on equity of -14.80% beat Celldex Therapeutics' return on equity.
Rigel Pharmaceuticals presently has a consensus price target of $36.80, suggesting a potential upside of 74.99%. Celldex Therapeutics has a consensus price target of $55.38, suggesting a potential upside of 172.11%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than Rigel Pharmaceuticals.
Summary
Rigel Pharmaceuticals beats Celldex Therapeutics on 10 of the 19 factors compared between the two stocks.
Get Rigel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rigel Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:RIGL) was last updated on 3/18/2025 by MarketBeat.com Staff
